US OptionsDetailed Quotes
RMTI241220P2500
- 0.40
- +0.10+33.33%
15min DelayClose Dec 19 16:00 ET
0.40High0.40Low
0.40Open0.30Pre Close8 Volume74 Open Interest2.50Strike Price320.00Turnover0.00%IV-2.44%PremiumDec 20, 2024Expiry Date0.45Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.13Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Rockwell Medical Stock Discussion
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Rockwell Medical Enters Into a Multi-Year Product Purchase Agreement With the World's Leading Provider of Dialysis Products and Services! Partnership is expected to generate upwards of $10 million in net sales for the Company in 2025, with incremental price increases each subsequent year and an effective term of up to five years
Benzinga· 5 mins ago
Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure and ...
Rockwell Medical Partners with HydroCare to Distribute and Install its Dry Acid Concentrate Mix System
Rockwell Medical (RMTI) has announced a partnership with HydroCare, a provider of dialysis water treatment systems, to distribute and install Rockwell's dry acid concentrate mix system in dialysis water rooms. The partnership involves HydroCare purchasing and installing Rockwell's DAMX45 system, which is 510(k) approved for exclusive use with the company's CitraP...
Risk Level: 6 (Moderate Risk)
The stock carries a moderate risk level of 6, indicating it is neither excessively risky nor completely safe. The company has a moderately profitable status with strong operational earnings and a good cash position, which counters the negative P/E ratio due to recent losses. Recent earnings for the company indicate profitability, aided by a net income of $1.66M for Q3 2024 and an EPS of $0.05. The positive catalyst , as the expansion of...
No comment yet